POLAREAN IMAGING PLC

Report Publication Announcement • May 14, 2021

National Storage Mechanism | Additional information

RNS Number : 6703Y

Polarean Imaging PLC

14 May 2021

Polarean Imaging plc

("Polarean" or the "Company")

Scientific presentations on hyperpolarised Xenon-129 at upcoming medical conferences

Polarean's investigational drug/device combination product to be prominently featured in presentations across a wide range of lung diseases

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational drug-device combination product to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces a number of abstracts and oral presentations highlighting the use of hyperpolarised Xenon-129 ("129Xe") will be made by leading academic researchers at the upcoming American Thoracic Society ("ATS 2021") virtual conference from 14-19 May 2021 and the International Society for Magnetic Resonance in Medicine ("ISMRM 2021") virtual conference from 15-20 May 2021.

23 abstracts related to the use of hyperpolarised 129Xe were accepted for presentation at ATS 2021, consisting of 8 oral presentations and 15 e-poster presentations. Polarean is also supporting ATS 2021 by hosting a virtual exhibit booth.

Additionally, 34 abstracts related to the use of hyperpolarised 129Xe were accepted for presentation at ISMRM 2021, consisting of 7 oral presentations and 27 e-poster presentations. Hyperpolarised 129Xe will also be discussed in a symposium on 17 May and in a sunrise session on 18 May. Furthermore, Polarean is supporting ISMRM 2021 by hosting a virtual exhibit booth. 

Richard Hullihen, Chief Executive Officer of Polarean commented: "We are pleased at the important work being done by leading investigators in the field of functional lung imaging. The data being presented at these key scientific meetings will further add to the body of evidence on hyperpolarised 129Xenon, highlighting several areas of unmet needs in current diagnostic modalities. Research of 129Xe MRI in interstitial lung disease, long-COVID-19, asthma, COPD and interventional pulmonology procedures are among the presentations that will be showcased."

A subset of the abstracts that will be presented during the ATS 2021 and ISMRM conferences are listed below.

Lead Author and ATS Abstract Title	Presentation Date	Abstract Number	ATS Notes
Mummy D et al. Regional Changes in Ventilation Following Bronchodilation in COPD Are Not Associated with Improved Gas Exchange on Xenon-129 MRI	16-May	1052	ORAL PRESENTATION Session A12: Sunday, May 16, 2021 (3:30-5pm)
Mcintosh M et al. Response to Benralizumab in Severe Asthma: Oscillometry and MRI Ventilation Defect Improvements in Participants with Abnormal FeNO	18-May	1111	ORAL PRESENTATION Session C4: Tuesday, May 18, 2021 (8-9:30am)
Eddy RL et al. Structure-Function Imaging Phenotypes of Asthma Using CT and 129Xe MRI	18-May	1112	ORAL PRESENTATION Session C4: Tuesday, May 18, 2021 (8-9:30am)
HE M et al. Probing Early-Stage Pulmonary Pathophysiology in Young Healthy E-cigarettes Users Using Hyperpolarized 129Xe MRI	18-May	1113	ORAL PRESENTATION Session C4: Tuesday, May 18, 2021 (8-9:30am)
Bdaiwi, AS et al. In Vivo Lung Morphometry of Lymphangioleiomyomatosis Using Hyperpolarized 129Xe Diffusion MRI	18-May	1114	ORAL PRESENTATION Session C4: Tuesday, May 18, 2021 (8-9:30am)
Bier E et al. Hyperpolarized 129Xe Magnetic Resonance Oscillation Imaging in Pulmonary Hypertension	18-May	1115	ORAL PRESENTATION Session C4: Tuesday, May 18, 2021 (8-9:30am)
Mummy D et al. Hyperpolarized 129Xe MRI Features Identify Functional Differences That Do Not Correlate with Chest CT in Patients with Idiopathic Pulmonary Fibrosis	18-May	1116	ORAL PRESENTATION Session C4: Tuesday, May 18, 2021 (8-9:30am)
Plummer JW et al. 129Xe gas-exchange MRI to detect diffusion abnormalities in children following bone-marrow transplantation	18-May	1166	ORAL PRESENTATION Session C15: Tuesday, May 18, 2021 (3:30-5pm)
Ruppert K et al. First Experience with Hyperpolarized 129Xe Imaging in a Recovered COVID-19 Patient	May 14-19	1998	E-poster Session TP031
Ranota TK et al. The Use of Hyper-polarized 129Xe Pulmonary MRI for Study of the Lung Damage in COVID-19 Survivors, Preliminary Results	May 14-19	3835	E-poster Session TP92
Matheson AM et al. This Is What COVID-19 Survival Looks Like: 129Xe MRI, Oscillometry and Pulmonary Function Measurements	May 14-19	4453	E-poster Session TP117
Kooner HK et al. CT Mucus Score Predicts Benralizumab Response in Severe Asthma	May 14-19	4531	E-poster Session TP120
Woodward E et al. Four Years Observation of the Emphysema Progression in Alpha-1 Antitrypsin Deficiency Using 3He/129Xe MRI	May 14-19	4574	E-poster Session TP121
Hamedani H et al. Monitoring Patients with Endobronchial Valve Interventions Using a Multifaceted Hyperpolarized (HP) Xenon Lung Function Assessment	May 14-19	4578	E-poster Session TP121
Bier E et al. Within-session Repeatability of Pulmonary 129Xe Static and Dynamic Spectroscopy	May 14-19	4589	E-poster Session TP122
Amzajerdian F et al. Exploring the Use of Continuous RF Irradiation for Xenon Polarization Transfer Contrast Imaging	May 14-19	4590	E-poster Session TP122

Lead Author and ISMRM Abstract Title	Presentation Date	Abstract Number	ISMRM Notes
Leewiwatwong S et al. Deep learning-based thoracic cavity segmentation for hyperpolarized 129Xe MRI	18-May	391	ORAL PRESENTATION (Session: Machine Learning for Image Analysis)
Mummy D et al. Regional Changes in Ventilation Following Bronchodilation in COPD Are Not Associated With Improved Gas Exchange on Xenon-129 MRI	19-May	589	ORAL PRESENTATION (Session: Lung)
Hahn A et al. Response of Hyperpolarized 129Xe MRI measures of ventilation and gas-exchange to anti-fibrotic treatment in Idiopathic Pulmonary Fibrosis	19-May	591	ORAL PRESENTATION (Session: Lung)
Hamedani H et al. Monitoring Patients with Endobronchial Valve Interventions Using a Multifaceted Hyperpolarized Xenon Lung Function Assessment	19-May	592	ORAL PRESENTATION (Session: Lung)
Marshall H et al. Hyperpolarised xenon ventilation MRI in difficult asthma; initial experience in a clinical setting	20-May	680	ORAL PRESENTATION (Session: Latest Advances in Hyperpolarized MRI)
Bier E et al. Extension of a Diagnostic Model for Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic Resonance Imaging and Spectroscopy	20-May	681	ORAL PRESENTATION (Session: Latest Advances in Hyperpolarized MRI)
Albert B J et al. Preclinical Hyperpolarized 129Xe Ventilation Imaging Using 3D Spiral (FLORET) Encoding	20-May	684	ORAL PRESENTATION (Session: Latest Advances in Hyperpolarized MRI)
Rao M. Imaging Beyond Perfusion Using 129Xe MRI	17-May		MEMBER-INITIATED SYMPOSIUM (Imaging Beyond Perfusion Using 129Xe MRI)
Woodward E et al. The Use of the 3He/129Xe MRI Lung Morphometry for a Longitudinal Observation of the Emphysema Progression in AATD Patients	17-May	1269	E-poster (Session: Novel Contrast Mechanisms)
Grist J et al. Utilizing hyperpolarised xenon MRI to detect gas transport deficiencies in post-COVID lungs	17-May	1736	E-poster (Session: MRI in COVID-19)
Ranota T et al. Feasibility of Single Breath-hold Isotropic Voxel 129Xe MRI in COVID-19 Survivors using a Key-Hole Method	17-May	1739	E-poster (Session: Role of Advanced Imaging in COVID-19)
Collier G et al. Imaging lung structure and function in acute COVID-19 patients with 129Xe and 1H MRI	17-May	1746	E-poster (Session: Role of Advanced Imaging in COVID-19)
Wild J. Hyperpolarized 129Xe MRI of the Lung	18-May		SUNRISE SESSION (Lung MRI: You Can Do It!)
Lu T et al. Convolutional Neural Networks for Super-resolution of Hyperpolarized 129Xe MR Images of the Lung	18-May	1968	E-poster (Session: Machine Learning to Reconstruct Accelerated Scans)
Gandhi D B et al. Comparison of Respiratory-Gating Weighting Algorithms in Neonatal Pulmonary UTE-MRI	18-May	2273	E-poster (Session: Pediatrics: Body Topics)
Chan H-F et al. Comparison of UTE 1H lung MRI with quantitative CT and hyperpolarized 129Xe diffusion-weighted MRI in IPF	19-May	3214	E-poster (Session: Lung: Disease Assessment)
Eaden J et al. Correlation of global and regional hyperpolarised 129-Xenon MRI with quantitative CT in patients with idiopathic pulmonary fibrosis	19-May	3216	E-poster (Session: Lung Disease Assessment)
Bdaiwi A S et al. Optimizing Acquisition and Analysis for Diffusion Weighted Hyperpolarized 129Xe MRI of Pediatric and Adult Lungs	20-May	3558	E-poster (Session: Hyperpolarization: Gas)
Astley J et al. Comparison of 3D convolutional neural networks and loss functions for ventilated lung segmentation using multi-nuclear hyperpolarized gas MRI	20-May	3560	E-poster (Session: Hyperpolarization: Gas)
Schulte R et al. Imaging Gas-Exchange Lung Function using Density-Weighted MRSI and Hyperpolarised 129Xe Gas	20-May	3562	E-poster (Session: Hyperpolarization: Gas)
Pratt R et al. A 129Xe/1H Switched Frequency High Pass Birdcage Coil for Hyperpolarized 129Xe Gas Lung Imaging in Neonates at 1.5 T	20-May	3563	E-poster (Session: Hyperpolarization: Gas)
Norquay G et al. Temporal correlation of alveolar-capillary 129Xe signal dynamics with the cardiac cycle	20-May	3564	E-poster (Session: Hyperpolarization: Gas)
Amzajerdian F et al. Feasibility of Xenon Polarization Transfer Contrast Imaging using Continuous RF Irradiation	20-May	3565	E-poster (Session: Hyperpolarization: Gas)
Hamedani H et al. Reproducibility Study Measuring Ventilation, Gas Exchange and Surface-to-Volume Using Hyperpolarized Xenon in Free-breathing Human Subjects	20-May	3566	E-poster (Session: Hyperpolarization: Gas)
Rao M et al. 3D isotropic spectroscopic imaging of hyperpolarized 129Xe in the human brain	20-May	3567	E-poster (Session: Hyperpolarization: Gas)
Chan H-F et al. Background field inhomogeneity effects on hyperpolarized 129Xe diffusion-weighted MRI at 1.5T and 3T	20-May	3568	E-poster (Session: Hyperpolarization: Gas)
Ruppert K et al. Detection of pulmonary abnormalities in a rabbit thoracic insufficiency syndrome model using hyperpolarized xenon-129 MRI	20-May	3569	E-poster (Session: Hyperpolarization: Gas)
Ball G et al. Modelling realistic Rb density and temperature distributions in a high throughput xenon-129 polariser	20-May	3570	E-poster (Session: Hyperpolarization: Gas)
Lu J et al. Template-based bias field correction of Hyperpolarized 129Xe Gas Ventilation MRI	20-May	3571	E-poster (Session: Hyperpolarization: Gas)
Bdaiwi A S et al. 2D and 3D Spiral for Diffusion Weighted MRI with Hyperpolarized 129Xe	20-May	3575	E-poster (Session: Hyperpolarization: Gas)
Driehuys B et al. Establishing the Structurally Limited Healthy RBC to Barrier Ratio for 129Xe Gas Exchange MRI	20-May	3791	E-poster (Session: Hyperpolarization: Gas & Non-Gas)
Bier E et al. Within-session Repeatability of Pulmonary 129Xe Static and Dynamic Spectroscopy	20-May	3792	E-poster (Session: Hyperpolarization: Gas & Non-Gas)
Doganay O et al. Assessment of Gas Exchange Parameters in Healthy and COPD Subjects using Hyperpolarized Xenon-129 MRI and Alveolar Gas-exchange Model	20-May	3793	E-poster (Session: Hyperpolarization: Gas & Non-Gas)
Loza L et al. A Comparison of Multi-breath Wash-in/Wash-out and RF-Contrast Hyperpolarized 129Xe Imaging Schemes for Quantifying Fractional Ventilation	20-May	3794	E-poster (Session: Hyperpolarization: Gas & Non-Gas)
Costa M L et al. Optimized Magnetization Decay Correction of Hyperpolarized Xe Ventilation Images Using Radial-Keyhole	20-May	3795	E-poster (Session: Hyperpolarization: Gas & Non-Gas)
Qian Y et al. Simulating the impact of asymmetric geometries on apparent alveolar septal wall thickness measurements with hyperpolarized xenon-129 MRI	20-May	3796	E-poster (Session: Hyperpolarization: Gas & Non-Gas)

Enquiries:

Polarean Imaging plc		www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer		Via Walbrook PR
Jonathan Allis, Chairman
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)			+44 (0)20 7710 7600
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)
Nick Adams / Fred Walsh (Corporate Broking)
Walbrook PR	Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy		Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space. 

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASFASALEFSEFI